Literature DB >> 20697156

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Sam D Molyneux1, Marco A Di Grappa, Alexander G Beristain, Trevor D McKee, Daniel H Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J Triche, Geoffrey A Wood, Lawrence S Kirschner, Rama Khokha.   

Abstract

Some cancers have been stratified into subclasses based on their unique involvement of specific signaling pathways. The mapping of human cancer genomes is revealing a vast number of somatic alterations; however, the identification of clinically relevant molecular tumor subclasses and their respective driver genes presents challenges. This information is key to developing more targeted and personalized cancer therapies. Here, we generate a new mouse model of genomically unstable osteosarcoma (OSA) that phenocopies the human disease. Integrative oncogenomics pinpointed cAMP-dependent protein kinase type I, alpha regulatory subunit (Prkar1a) gene deletions at 11qE1 as a recurrent genetic trait for a molecularly distinct subclass of mouse OSA featuring RANKL overexpression. Using mouse genetics, we established that Prkar1a is a bone tumor suppressor gene capable of directing subclass development and driving RANKL overexpression during OSA tumorigenesis. Finally, we uncovered evidence for a PRKAR1A-low subset of human OSA with distinct clinical behavior. Thus, tumor subclasses develop in mice and can potentially provide information toward the molecular stratification of human cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697156      PMCID: PMC2929719          DOI: 10.1172/JCI42391

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

Review 1.  Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.

Authors:  John T Swarthout; Richard C D'Alonzo; Nagarajan Selvamurugan; Nicola C Partridge
Journal:  Gene       Date:  2002-01-09       Impact factor: 3.688

2.  Detection of c-fos expression in benign and malignant musculoskeletal lesions.

Authors:  J S Weisstein; R J Majeska; M J Klein; T A Einhorn
Journal:  J Orthop Res       Date:  2001-05       Impact factor: 3.494

3.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

Review 4.  Etiology of osteosarcoma.

Authors:  Bruno Fuchs; Douglas J Pritchard
Journal:  Clin Orthop Relat Res       Date:  2002-04       Impact factor: 4.176

5.  Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.

Authors:  K Mori; B Le Goff; M Berreur; A Riet; A Moreau; F Blanchard; C Chevalier; I Guisle-Marsollier; J Léger; J Guicheux; M Masson; F Gouin; F Rédini; D Heymann
Journal:  J Pathol       Date:  2007-04       Impact factor: 7.996

6.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

7.  Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas.

Authors:  Ana Patiño-García; Elena Sotillo Piñeiro; Marta Zalacaín Díez; Leire Gárate Iturriagagoitia; Federico Antillón Klüssmann; Luis Sierrasesúmaga Ariznabarreta
Journal:  J Pediatr Hematol Oncol       Date:  2003-05       Impact factor: 1.289

8.  Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma.

Authors:  Ching C Lau; Charles P Harris; Xin-Yan Lu; Laszlo Perlaky; Sheila Gogineni; Murali Chintagumpala; John Hicks; Mark E Johnson; Nelson A Davino; Andrew G Huvos; Paul A Meyers; John H Healy; Richard Gorlick; Pulivarthi H Rao
Journal:  Genes Chromosomes Cancer       Date:  2004-01       Impact factor: 5.006

9.  Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast.

Authors:  Romain Dacquin; Michael Starbuck; Thorsten Schinke; Gérard Karsenty
Journal:  Dev Dyn       Date:  2002-06       Impact factor: 3.780

10.  Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.

Authors:  Qiang Fu; Robert L Jilka; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

View more
  50 in total

1.  Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.

Authors:  Kun Wang; Jinmin Zhao; Maolin He; Mitra Fowdur; Tenglong Jiang; Shuju Luo
Journal:  Tumour Biol       Date:  2015-08-15

2.  RANKL inhibitors for osteosarcoma treatment: hope and caution.

Authors:  Eva M Trinidad; Eva González-Suárez
Journal:  Ann Transl Med       Date:  2016-12

3.  Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.

Authors:  Sara Del Mare; Kyle C Kurek; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  Am J Cancer Res       Date:  2011-04-03       Impact factor: 6.166

4.  Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects.

Authors:  Emmanouil Saloustros; Sisi Liu; Edward L Mertz; Nisan Bhattacharyya; Matthew F Starost; Paraskevi Salpea; Maria Nesterova; Michael Collins; Sergey Leikin; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2016-08-04       Impact factor: 4.102

5.  Knockdown of PRKAR1A, the gene responsible for Carney complex, interferes with differentiation in osteoblastic cells.

Authors:  Mei Zhang; Parmeet K Manchanda; Dayong Wu; Qianben Wang; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2014-02-07

Review 6.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 7.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

Review 8.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

9.  QUANTIFYING NANOPARTICLE TRANSPORT IN VIVO USING HYPERSPECTRAL IMAGING WITH A DORSAL SKINFOLD WINDOW CHAMBER.

Authors:  Trevor D McKee; Juan Chen; Ian Corbin; Gang Zheng; Rama Khokha
Journal:  J Innov Opt Health Sci       Date:  2012-11-26

Review 10.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.